Core Viewpoint - The company reported a significant decline in revenue and net profit for the year 2024, indicating financial challenges and operational difficulties [1][2]. Financial Performance Summary - The company's operating revenue for 2024 was 1.017 billion yuan, a decrease of 29.16% compared to 2023 [2]. - The net profit attributable to shareholders for 2024 was -28.71 million yuan, down 158.95% year-on-year [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -31.29 million yuan, reflecting a 193.25% decrease from the previous year [2]. - The net cash flow from operating activities was -30.85 million yuan, a decline of 167.14% compared to the previous year [2]. Q1 2025 Performance - In the first quarter of 2025, the company achieved an operating revenue of 286.19 million yuan, representing a year-on-year increase of 18.94% [3]. - The net profit attributable to shareholders for Q1 2025 was -5.12 million yuan, compared to -3.69 million yuan in the same period last year, indicating a worsening situation [3]. - The net profit after deducting non-recurring gains and losses for Q1 2025 was -5.62 million yuan, also showing a decline from -3.98 million yuan year-on-year [3]. - The net cash flow from operating activities for Q1 2025 was -8.89 million yuan, which is a 31.79% increase in negative cash flow compared to the previous year [3]. Fundraising and Projects - The company raised a total of 376.06 million yuan through its stock issuance, with a net amount of 319.06 million yuan allocated to various projects including feed production and health industry initiatives [4]. - The total issuance costs amounted to 57.01 million yuan, with underwriting fees constituting 31.80 million yuan [5].